...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Interferon beta in relapsing-remitting multiple sclerosis : An eight years experience in a specialist multiple sclerosis centre.
【24h】

Interferon beta in relapsing-remitting multiple sclerosis : An eight years experience in a specialist multiple sclerosis centre.

机译：复发性多发性硬化症中的干扰素β：在专业的多发性硬化症中心拥有八年的经验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sirs: I read with interest the article by Rio and co-workers that was recently published in your Journal . Clearly, as the authors point out, the major deficiency in the current therapeutic literature in multiple sclerosis (MS) is the lack of convincing long-term data. Thus, the longest available placebo-controlled data goes out to only 5 years of treatment , whereas the outcome of MS is well known to evolve over a considerably longer time-frame. Nevertheless, placebo-controlled trials of more than 2-3 years are impractical and possibly unethical. As a result, I fully agree with the authors' assertion that observational studies have certain distinct advantages over controlled trials by potentially providing data on the behavior of large patient cohorts followed for extended treatment periods. Indeed, it seems clear that the use of such non-experimental observational data will become increasingly important in the future. However, these potential advantages of observational data can only be realized ifthe cohort-size is quite large and the observation interval is quite long relative to randomized trials, and if the observational data are analyzed in an appropriate manner (which can often be quite complicated).
机译：先生：我很感兴趣地阅读了力拓及其同事最近在您的《华尔街日报》上发表的文章。显然，正如作者指出的那样，当前多发性硬化症（MS）治疗文献中的主要缺陷是缺乏令人信服的长期数据。因此，最长的可用安慰剂对照数据仅用于治疗5年，而众所周知，MS的结果会在相当长的时间内发展。然而，超过2-3年的安慰剂对照试验是不切实际的，甚至可能是不道德的。结果，我完全同意作者的主张，即观察性研究相对于对照试验具有某些明显的优势，因为它有可能提供有关长期治疗后大量患者队列行为的数据。确实，很明显，这种非实验性观察数据的使用在将来将变得越来越重要。但是，只有相对于随机试验，队列规模很大且观察间隔较长，并且以适当的方式分析观察数据（通常会非常复杂），才能实现观察数据的这些潜在优势。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号